A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Impact of a Single Intravenous Dose of MTP-131 (Bendavia) on Skeletal Muscle Function in the Elderly

Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Impact of a Single Intravenous Dose of MTP-131 (Bendavia) on Skeletal Muscle Function in the Elderly

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Elamipretide (Primary)
  • Indications Mitochondrial disorders; Musculoskeletal disorders
  • Focus Therapeutic Use
  • Acronyms MOTION
  • Sponsors Stealth BioTherapeutics
  • Most Recent Events

    • 01 Feb 2017 Status changed from recruiting to completed.
    • 19 Sep 2016 Primary endpoint has not been met. (Mitochondrial energy production (ATPmax)), as reported by a Stealth BioTherapeutics media release.
    • 19 Sep 2016 The data from this trial were presented at the Late Breaker Poster Session of the Heart Failure Society of America Annual Scientific Meeting, as reported by a Stealth BioTherapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top